|
|
 |
 |
| |
 Printable version |
Management of side effects associated with antiangiogenic treatment in renal cell carcinoma |
Bulletin du Cancer. Volume 97, 73-82, Cancers du rein, Synthèse
|
 Résumé
Article gratuit
|
Author(s) : A Fléchon, H Boyle, S Négrier |
Summary : The recent development of antiangiogenic agents has revolutionized the management of renal cell carcinoma. In less than two-years, the French health authorities have approved the use of four drugs (sorafenib, sunitinib bevacizumab, temsirolimus) for the treatment of locally advanced or metastatic renal cell carcinoma. A fifth drug (everolimus) should be on the market some time. Clinicians have changed their practice and are faced with a number of new adverse events. The management of toxic effects is essential to ensure treatment compliance and patient quality of life. The present report describes in detail the adverse events associated with each therapeutic class and the management of side effects. |
Keywords : antiangiogenic drugs, toxicity, patient management |
|
